ReviewCold Spring Harbor perspectives in medicine2020
The Different Facets of Liquid Biopsy: A Kaleidoscopic View.
Review in Cold Spring Harbor perspectives in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Roles and Applications of Circulating Tumor-Derived RNAs in Sarcoma Patients: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Clinical utility and diagnostic value of tumor-educated platelets in lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Inferring tissue origin from cell-free DNA in metastatic cancer.Cancer metastasis reviews · 2026Review
- Advancements in CRISPR/Cas Technologies for Sensitive Cancer Detection: Mechanisms, Platforms, and Clinical Translation Roadmap.Diagnostics (Basel, Switzerland) · 2026Review
- Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.European journal of medical research · 2025Review
- Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL).The journal of liquid biopsy · 2025Article
- A Compact Prism-Based Microscope for Highly Sensitive Measurements in Fluid Biopsy.Journal of biophotonics · 2025Article
- Liquid biopsy: paving a new avenue for cancer research.Cell adhesion & migration · 2024Review
- Diagnostics and Therapy for Malignant Tumors.Biomedicines · 2024Review
- Recent Technologies towards Diagnostic and Therapeutic Applications of Circulating Nucleic Acids in Colorectal Cancers.International journal of molecular sciences · 2024Review
- Biomarkers for Early Cancer Detection: A Landscape View of Recent Advancements, Spotlighting Pancreatic and Liver Cancers.ACS pharmacology & translational science · 2024Review
- The role of long non-coding RNAs in angiogenesis and anti-angiogenic therapy resistance in cancer.Molecular therapy. Nucleic acids · 2022Review
- Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer.International journal of molecular sciences · 2022Article
- Article
- Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer.Diagnostics (Basel, Switzerland) · 2022Article
- From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades.Frontiers in immunology · 2022Review
- Liquid biopsy approaches and immunotherapy in colorectal cancer for precision medicine: Are we there yet?Frontiers in oncology · 2022Review
- Cell-free DNA as a biomarker in cancer.Extracellular vesicles and circulating nucleic acids · 2022Review
- Clinical Biomarkers for Early Identification of Patients with Intracranial Metastatic Disease.Cancers · 2021Review
- A DNA Methylation-Based Gene Signature Can Predict Triple-Negative Breast Cancer Diagnosis.Biomedicines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current limitations of cancer diagnosis and molecular profiling based on invasive tissue biopsies or clinical imaging have led to the development of the liquid biopsy field. Liquid biopsy includes the isolation of circulating tumor cells (CTCs), circulating free or tumor DNA (cfDNA or ctDNA), extracellular vesicles (EVs), and tumor-educated platelets (TEPs) from body fluid samples and their molecular characterization to identify biomarkers for early cancer diagnosis, prognosis, therapeutic prediction, and follow-up. These innovative biosources show similar features as the primary tumor from where they originated or interacted. This review describes the different technologies and methods used for processing these biosources as well as their main clinical applications with their advantages and limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.